The combination therapy of gemcitabine, cisplatin, or carboplatin with an ADC was also tested in vivo in different xenograft models (17-20).  In two recent studies, the combination of gemcitabine with an anti-c-Met ADC (18), and anti-CD25 ADC (19) resulted in synergistic anti-tumor activity both in vitro and in vivo. Here, MET is linked to neoplasm.